Primary central nervous system lymphoma in daily practice and the role of autologous stem cell transplantation in relapsed disease: A retrospective multicenter study
dc.contributor.author | Erkurt, MA | |
dc.contributor.author | Berber, I | |
dc.contributor.author | Tekgunduz, E | |
dc.contributor.author | Dogu, MH | |
dc.contributor.author | Korkmaz, S | |
dc.contributor.author | Demir, C | |
dc.contributor.author | Yilmaz, M | |
dc.contributor.author | Akay, OM | |
dc.contributor.author | Pala, C | |
dc.contributor.author | Bilen, Y | |
dc.contributor.author | Kaya, E | |
dc.contributor.author | Sari, I | |
dc.contributor.author | Sencan, M | |
dc.contributor.author | Kuku, I | |
dc.contributor.author | Altuntas, F | |
dc.contributor.author | Dal, MS | |
dc.contributor.author | Aydogdu, I | |
dc.date.accessioned | 2024-07-18T12:07:57Z | |
dc.date.available | 2024-07-18T12:07:57Z | |
dc.description.abstract | We investigated the course of 54 patients presenting with primary central nervous system lymphoma, who were treated in daily practice. The patients were treated with chemotherapy and/or radiotherapy and/or intrathecal chemotherapy. At a median follow-up period of 23 months (range 1-71), median relapse-free survival (RFS) and overall survival (OS) were not reached. Estimated 2-year RFS and OS rates were 42% and 48%, respectively. Ten relapsed PCNSL patients underwent ASCT. Complete remission rate of these patients was 40%, with 20% treatment-related mortality. Estimated 2-year RFS and OS rates were 37% and 40%, respectively. The prognosis of patients with PCNSL, who received off-study treatment, is still dismal. (c) 2016 Elsevier Ltd. All rights reserved. | |
dc.identifier.issn | 1473-0502 | |
dc.identifier.uri | http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/10726 | |
dc.language.iso | English | |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | |
dc.subject | PRIMARY CNS LYMPHOMA | |
dc.subject | HIGH-DOSE METHOTREXATE | |
dc.subject | WHOLE-BRAIN RADIOTHERAPY | |
dc.subject | RECURRENT PRIMARY CNS | |
dc.subject | INTENSIVE CHEMOTHERAPY | |
dc.subject | PHASE-II | |
dc.subject | IMMUNOCOMPETENT PATIENTS | |
dc.subject | DEFERRED RADIOTHERAPY | |
dc.subject | INTRAOCULAR LYMPHOMA | |
dc.subject | DIAGNOSIS | |
dc.title | Primary central nervous system lymphoma in daily practice and the role of autologous stem cell transplantation in relapsed disease: A retrospective multicenter study | |
dc.type | Article |